Korro Bio reports Q3 EPS ($1.92), consensus ($2.68)

Reports Q3 revenue $1.09M, consensus $411,560. The company said, “Korro estimates that it will incur one-time restructuring charges of approximately $2.4 million including employee severance, benefits, and related termination costs, the majority of which Korro expects to recognize during the fourth quarter of 2025.”